BIBLIOGRAPHY:

1. A. Novakova, L. and Vlckova, H. (2009), A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation, Analytica Chimica Acta, vol: 656, pg: 8-11.
2. A. Kirthi (2014), A review on bioanalytical method development and validation by RP – HPLC, Journal of Global Trends in Pharmaceutical Sciences, vol 5 (4): pg: 2265-2014.
3. B. Vogeser, M. and Sege, C. (2008), A. decade of HPLC–MS/MS in the routine clinical laboratory - Goals for further developments. Clinical Biochemistry, vol: 41, pg: 649.
4. Cha. Xu, R.N., Fan, L., Rieser, M.J. and El-Shourbagy, T.A. (2007), Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, vol: 44, pg: 342.
5. D. Holcapek, M., Kolarova, L. and Nobilis, M. (2008), High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites, Analytical and Bioanalytical Chemistry, vol: 391, pg: 59.
6. Espada A, Molina-Martin M, Dage J, Kuo MS. (2008), Application of LC/MS and related techniques to high through put drug discovery. Drug Discov. Today, vol: 13 (9-10), pg: 417.
7. E. Murugan S, Pravallika N, Sirisha P, Chandrakala K.(2013), A review on bioanalytical method development and validation by using LC-MS/MS, Journal of Chemical and Pharmaceutical Sciences, vol: 6, pg: 41-46.
8. F. Plumb RS, Dear GJ, Mallett DN, Higton DM, Pleasanc S, Biddlecombe RA. (2001), Quantitative analysis of pharmaceuticals in biological fluids using high-performance liquid chromatography coupled to mass spectrometry: a review, Xenobiotica, vol: 31 (599) pg: 5-9.
9. F. Yanli Deng, Armina Madatian (2011), Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects, Drug Metabolism And Disposition, by The American Society for Pharmacology and Experimental Therapeutics, Vol. 39, No. 9, pg: 1734–1746.
10. G. Rambabu Maddela (2014), Liquid chromatography–tandem mass spectrometric assay for eltrombopag in human plasma: A pharmacokinetic study using eltrombopag, Journal of Pharmaceutical and Biomedical Analysis ,Vol. 98, pg: 68–73.

11. Gorge. Wei Zeng (2010), Estimation of sitagliptinin human plasma by protein precipitation and tandem mass spectrometry, Journal of Chromatography B, Vol. 878, pg: 1817–1823.

12. Gorge. Wei Zeng (2008), Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry method, Journal of Pharmaceutical and Biomedical Analysis, vol: 46, pg: 534–542.

13. H. Nageswara Rao (2011), Molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine, Talanta, vol: 85, pg: 950– 957.

14. Hari Ramakrishna Nirogi (2008), Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid–liquid extraction, Biomedical Chromatography, vol: 22, pg: 214-222.

15. I Laura Else (2010), Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds, Journal of Chromatography B, vol: 878, pg: 1455–1465.

16. I Lieven Baert (2009), Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment, vol: 72, pg: 502–508.

17. I. Dinesh S.Patel (2011), LC–MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study European Journal of Pharmaceutics and Biopharmaceutics, Acta Pharmaceutica Sinica B, vol:2211, pg: 1-14.

18. J.V.Sreedevi (2011), LC-MS Method Development and validated for the estimation of Felodipine in human plasma and Stability studies of freeze thaw analyte, International Journal of Pharma Sciences and Research, Vol.2 (2), pg: 65-73.

19. K. Gayatri Gullipalli (2009), Development and Validation of simultaneous estimation of Flupirtine Maleate and Paracetamol in Bulk and Dosage Form by RP-HPLC, International Journal of Pharmaceutical Science Invention, Vol 3(5), pg: 49-59.

20. K. Singaram Kathirvel (2013), Stress Degradation Studies on Flupirtine Maleate by Stability-Indicating isocratic RP-HPLC Method, Chromatography Research International, vol:1, pg: 1-6.

21. K. N. V. S. Ramakrishna (2004), Development of Simple, sensitive and rapid liquid chromatographic / electrospray ionization tandem mass spectrometric method for the

quantification of lacidipine in human plasma Journal of Mass Spectrometry, vol:39, pg: 824–832.

22. K. A.B. Baranda (2005), liquid–liquid extraction procedure for five 1,4-dihydropyridines calcium channel antagonists from human plasma using experimental design, Talanta, vol:67, pg: 933–941.

23. L. J.A. Lo´pez (2000), High-performance liquid chromatography with amperometric detection applied to the screening of 1,4-dihydropyridines, Journal of Chromatography A, vol: 870, pg: 105–114.

24. Ling Tang (2008), Ultra-performance liquid chromatography–tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study, Journal of Pharmaceutical and Biomedical Analysis, vol: 47, pg: 923–928.

25. M. Pellegatti (1992), Validation of a high-performance liquid chromatographic-radioimmunoassay method for the determination of lacidipine in plasma, Journal of Chromatography, Biomedical Applications, vol: 573, pg: 105-11.

26. Mna B. Baranda (2006), Instability of calcium channel antagonists during sample preparation for LC–MS–MS analysis of serum samples, Forensic Science International, vol:156, pg: 23–34.

27. N. Paolo Rossato (1993), Investigation into lacidipine and related metabolites by high-performance liquid chromatography-mass spectrometry, Journal of Chromatography, vol: 647, pg: 155-166.

28. N. Rihana Parveen Shaik (2013), LC–MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study, Journal of Pharmaceutical Analysis, vol: 6, pg:489–499.

29. O. Manish Yadav (2010), LC-MS/MS separation and estimated simultaneously for the determination of tolterodine and its active, 5-hydroxymethyl tolterodine in human plasma, Chromatographia, vol: 72, pg: 255-264.

30. S. Ashutosh Kumar (2013), Development and validation of Tolterodine Tartrate in Bulk as well as in Pharmaceutical Formulation by RP-HPLC, International Journal of Pharmacy and Pharmaceutical Sciences, Vol 5 - 3, (2013), pg: 665-671.

31. S. Ramesh Yanamandra (2012), New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples, Sci Pharm., vol: 80, pg: 101–114.

32. S. Radha Krishna (2009), Stability-Indicating HPLC Method for the Determination of Related Substances, Rasaya. J. Chem, vol: 2 – 1, pg: 144-150.

33. S. S. Reddy (2012), Identification, isolation and quantification of unknown impurity in tolterodine tartrate tablets by stability indicating HPLC method, Journal of Chemical and Pharmaceutical Research, vol: 4 -7, pg: 3659-3664.

34. S. Lakshmana Rao (2013), Analytical Method Development and Validation for the Simultaneous Estimation of Febuxostat and Ketorolac In Tablet Dosage Forms by RP-HPLC, International Journal of Pharmaceutical, Chemical and Biological Sciences, vol 3 - 3, pg: 571-576.

35. S.Prathap (2014), Analytical Method Development and Validation for Simultaneous Estimation of Febuxostat And Ketorolac In Bulk And Pharmaceutical Dosage Form In Rat Plasma by RP-HPLC, Indo American Journal of Pharm Research, Vol 4 – 4, pg: 1717-1729.

36. S.Babu Rao Chandu (2013), Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method. Febuxostat (FB) in human plasma, SpringerPlus, vol 2 - 194, pg: 1-10.

37. S. Monita Gide (2014), Method Development and Validation for Determination of Febuxostat from Spiked Human Plasma Using RP-HPLC with UV Detection, Chromatography Research International, vol 4, pg: 1-5.

38. Vaka VR (2013), LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application with 100 µL human plasma, Biomed Chromatogr. Vol 27 -11, pg: 1406-1412.

39. Vis Shi Z (2013), Development of a simple LC-MS/MS method for the determination of febuxostat in human plasma and its application to a bioequivalence, Pharmazie, vol: 68 – 6, pg: 396-400.

40. V. Mullett, W.M. (2007), Determination of drugs in biological fluids by direct injection of samples for liquid-chromatographic analysis. Journal of Biochemical and Biophysical methods, vol: 70, pg: 263-270.

41. V. Novakova, L. and Vlckova, H. (2009), A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. Analytica Chimica Acta, vol: 656, pg: 8-12.

42. V. Ma, J., Shi, J., Le, H., Cho, R., Huang, J.C., Miao, S. and Wong, B.K. (2008), A fully automated plasma protein precipitation sample preparation method for LC-

MS/MS bioanalysis. Journal Chromatography B Analytical Technology Biomedical Life Sciences, vol: 862, pg: 219-225.

43. W. Pawliszyn, J. (2003), Sample preparation, Analytical Chemistry, vol: 75, pg: 2543-2546.

44. Will Silvestre, C.I., Santos, J.L., Lima, J.L. and Zagatto, E.A. (2009), Liquid-liquid extraction in flow analysis: A critical review, Analytica Chimica Acta, vol: 652, pg: 54-59.

45. McDowall, R.D. (1989), Sample preparation for biomedical analysis. Journal of Chromatography, vol: 492, pg: 3-5.

46. McDowall, R.D., Doyle, E., Murkitt, G.S. and Picot, V.S. (1989), Sample preparation for the HPLC analysis of drugs in biological fluids, Journal of Pharmaceutical and Biomedical Analysis, vol: 7, pg: 1087-1090.

47. Zie Hennion, M.C (1999), Solid-phase extraction: method development, sorbents, and coupling with liquid chromatography, Journal Chromatography A, vol: 856, pg: 3-8.

48. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at: http://www/ fda.gov/cder/guidance/index.htm.

49. Guideline on Bio Aanalytical Method Validation, Science and Medicinal Health, European Medicines Agency (EMEA), EMEA/CHMP/EWP/192217/2009; 21 July 2011.

50. US DHHS, FDA and CDER. Draft Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2013.
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.